GeoVax CEO to Discuss MVA-Based Vaccine Platform for Broader Infectious Disease Preparedness in Tribe Public Webinar

Registration is now open for Tribe Public's CEO Presentation and Q&A Webinar featuring GeoVax Labs, Inc. (Nasdaq: GOVX) Chairman and CEO David Dodd. The event, titled "Ebola, Marburg, Hantavirus, Mpox and Beyond: Building a Resilient Infectious Disease Preparedness Strategy," is scheduled for May 28, 2026, at 8:00 a.m. Pacific Time / 11:00 a.m. Eastern Time. The webinar will address the need for platform-based vaccine technologies to counter multiple viral threats, including orthopox and hemorrhagic fever viruses.

David Dodd emphasized the limitations of single-threat approaches, stating, "Ebola, Marburg, Mpox and most recently Hantavirus concerns all reinforce the same lesson: global preparedness strategies must evolve beyond reactive, single-threat approaches." GeoVax is advancing versatile MVA-based vaccine technologies designed to support broader infectious disease preparedness and address critical gaps in biodefense infrastructure. The webinar will explore why emerging outbreaks continue to expose vulnerabilities in global response systems and the potential role of MVA-based technologies in addressing these gaps.

The discussion comes as GeoVax progresses its lead program, GEO-MVA, a Modified Vaccinia Ankara (MVA)-based vaccine targeting mpox and smallpox. The program is advancing under an expedited regulatory pathway, with a pivotal Phase 3 clinical trial planned for the second half of 2026. The company aims to address global needs for expanded orthopoxvirus vaccine supply and biodefense preparedness. Additionally, GeoVax is developing Gedeptin®, a gene-directed enzyme prodrug therapy for oncology, which has completed a Phase 1/2 trial in head and neck cancer.

To register for the complimentary Zoom webinar, visit Ebola-May-2026.TribePublic.com. Participants can submit questions in advance to [email protected] or use Zoom's chat feature during the live event. Tribe Public Managing Member John F. Heerdink, Jr. will host and moderate.

GeoVax Labs is a clinical-stage biotechnology company focused on infectious disease and cancer vaccines and immunotherapies. The company's MVA-based platform offers potential scalability and resilience for domestic vaccine manufacturing, which is critical for pandemic preparedness. The webinar underscores the importance of proactive strategies in global biodefense, as highlighted by recent outbreaks of Ebola, Marburg, and Hantavirus.